30 likes | 246 Views
Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival. 0.1. 0.2. 0.5. 1.0. 2.0. 5.0. 10.0. Favours rituximab. Favours control. OR=odds ratio. Adapted from Vidal et al. ASH 2007, abstract 3408. Dense-R-CHOP-14 Trial Survival Results. Percentage.
E N D
Rituximab as Maintenance Therapy for Patients with Follicular Lymphona: Overall Survival 0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours rituximab Favours control OR=odds ratio Adapted from Vidal et al. ASH 2007, abstract 3408.
Dense-R-CHOP-14 Trial Survival Results Percentage Poor prognosis (aaIPI 3-5) Adapted from Pfreundschuh et al. ASH 2007, abstract 789.
R-FCM in CLL: Response Rates Near PR Complete Response MRD-positive CR PR Grade 3 or 4 neutropenias 0 10 20 30 40 50 60 70 80 90 100 OR 92%; grade 3/4 neurtropenia 8%. Adapted from Bosch et al. ASH 2007, abstract 626.